GlassScriptPhysician profile
Melanie Czup
NPI 1376150920
$9,633.86
in general payments reported to CMS, 2019-2025
37 companies · $4,995 in 2025
The $4,995 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.59 · 2022: $65.42 · 2023: $2,017 · 2024: $2,519 · 2025: $4,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,118 · Travel and Lodging: $1,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,117.92 |
| Travel and Lodging | $1,412.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,446.28 | 2023-2025 | Fasenra, Tezspire, Breztri |
| Intuitive Surgical, INC. | $1,203.61 | 2025 | |
| Glaxosmithkline, LLC. | $1,180.88 | 2023-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Inspire Medical Systems, INC. | $1,128.80 | 2024-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $587.63 | 2023-2025 | Ofev, Jascayd, Spiriva Respimat |
| Harmony Biosciences LLC | $467.49 | 2023-2025 | Wakix |
| Merck Sharp & Dohme LLC | $350.51 | 2023-2025 | Zerbaxa, Recarbrio, Winrevair |
| Regeneron Healthcare Solutions, INC. | $341.83 | 2023-2025 | Dupixent |
| Genzyme Corporation | $310.87 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $301.42 | 2023-2025 | Purified Cortrophin Gel |
| Mylan Specialty L.P. | $247.54 | 2022-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $239.47 | 2023-2025 | |
| Electromed, INC. | $150.51 | 2024-2025 | Smartvest |
| Amgen INC. | $147.88 | 2023-2025 | Tezspire |
| United Therapeutics Corporation | $140.35 | 2022-2025 | Tyvaso, Tyvaso, Orenitram |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $139.76 | 2025 | Ohtuvayre |
| Insmed, INC. | $137.66 | 2023-2025 | Brinsupri, Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $133.00 | 2022-2025 | Glassia |
| Bayer Healthcare Pharmaceuticals INC. | $131.89 | 2023-2024 | |
| Pulmonx Corporation | $131.26 | 2023-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Grifols USA, LLC | $87.29 | 2025 | Prolastin-C Liquid |
| Genentech USA, INC. | $83.45 | 2025 | Xolair |
| Axsome Therapeutics, INC. | $76.49 | 2023-2025 | Sunosi |
| Viatris Specialty LLC | $65.16 | 2025 | Yupelri |
| Baxter Healthcare | $65.03 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Mallinckrodt Hospital Products INC. | $50.64 | 2024-2025 | Acthar |
| La Jolla Pharmaceutical Company | $45.82 | 2023-2024 | Giapreza |
| Actelion Pharmaceuticals US, INC. | $40.48 | 2025 | Opsynvi, Uptravi, Opsumit |
| Philips North America LLC | $35.00 | 2024 | (Ak6) Vest Therapy |
| 3b Medical, INC. | $31.86 | 2024-2025 | Luna |
| Resmed Corp | $30.95 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.66 | 2021 | |
| Fisher & Paykel Healthcare INC | $21.12 | 2025 | Fisher & Paykel Healthcare |
| Lundbeck LLC | $15.93 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.83 | 2024 | |
| Liquidia Technologies, INC. | $14.62 | 2025 | Yutrepia |
| Novo Nordisk INC | $13.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Czup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.